文献速递乳腺癌

新辅助单药他拉唑帕利治疗可手术gBRCA阳性乳腺癌

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
PubMed 文献 · J Clin Oncol · 2019-08-28

这项研究评估了已知gBRCA致病性变异的可手术乳腺癌患者接受6个月单药口服他拉唑帕利(1 mg/日)新辅助治疗的病理反应。20例患者中RCB-0率为53%,RCB-0/I率为63%,常见3级贫血需输血。单药他拉唑帕利不化疗可产生实质性病理缓解且毒性可控。

要点

  • gBRCA阳性可手术乳腺癌中,6个月单药他拉唑帕利RCB-0率达53%。
  • RCB-0/I率为63%,支持进一步开展更大规模新辅助试验。
  • 40%患者出现3级贫血需输血,9例需减量,毒性总体可控。

核心结论

  • 单药口服他拉唑帕利每日一次持续6个月不联合化疗,在gBRCA阳性可手术乳腺癌中产生较高的RCB-0率,毒性可管理。

研究设计与样本

  • 单臂研究,纳入20例1 cm或以上浸润性肿瘤且gBRCA阳性的可手术乳腺癌患者,排除HER2阳性。
  • 治疗前活检后接受6个月每日一次口服他拉唑帕利1 mg,随后行根治性手术。
  • 主要终点为残余肿瘤负荷(RCB)。

主要发现

  • 20例患者中位年龄38岁(范围23至58岁),16例gBRCA1阳性,4例gBRCA2阳性。
  • 1例术前选择化疗未纳入RCB分析;RCB-0(病理完全缓解)率为53%,RCB-0/I率为63%。
  • 8例(40%)出现3级贫血需输血,3例3级中性粒细胞减少,1例4级血小板减少。
  • 常见1或2级毒性为恶心、乏力、中性粒细胞减少、脱发、头晕和呼吸困难;9例需减量。

临床怎么用

  • 对于gBRCA阳性可手术乳腺癌患者,单药他拉唑帕利新辅助治疗可作为不化疗的一种选择,但需密切监测贫血并及时输血支持。

局限性

  • 样本量小(20例),为单臂研究,无对照组。
  • 1例患者术前接受化疗未纳入RCB分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer. METHODS: Eligibility included 1 cm or larger invasive tumor and gBRCA-positive disease. Human epidermal growth factor receptor 2-positive tumors were excluded. Twenty patients underwent a pretreatment biopsy, 6 months of once per day oral talazoparib (1 mg), followed by definitive surgery. Patients received adjuvant therapy at physician's discretion. The primary end point was residual cancer burden (RCB). With 20 patients, the RCB-0 plus RCB-I response rate can be estimated with a 95% CI with half width less than 20%. RESULTS: Twenty patients were enrolled from August 2016 to September 2017. Median age was 38 years (range, 23 to 58 years); 16 patients were gBRCA1 positive and 4 patients were gBRCA2 positive. Fifteen patients had triple-negative breast cancer (estrogen receptor/progesterone receptor < 10%), and five had hormone receptor-positive disease. Five patients had clinical stage I disease, 12 had stage II, and three had stage III, including one patient with inflammatory breast carcinoma and one with metaplastic chondrosarcomatous carcinoma. One patient chose to receive chemotherapy before surgery and was not included in RCB analyses. RCB-0 (pathologic complete response) rate was 53% and RCB-0/I was 63%. Eight patients (40%) had grade 3 anemia and required a transfusion, three patients had grade 3 neutropenia, and 1 patient had grade 4 thrombocytopenia. Common grade 1 or 2 toxicities were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea. Toxicities were managed by dose reduction and transfusions. Nine patients required dose reduction. CONCLUSION: Neoadjuvant single-agent oral talazoparib once per day for 6 months without chemotherapy produced substantial RCB-0 rate with manageable toxicity. The substantive pathologic response to single-agent talazoparib supports the larger, ongoing neoadjuvant trial (ClinicalTrials.gov identifier: NCT03499353).

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2019. PMID: 31461380. doi:10.1200/JCO.19.01304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。